Retaplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-segment elevation myocardial infarction

Victor Serebruany

Research output: Contribution to journalArticle

Abstract

Question. In people with diabetes and ST-segment elevation myocardial infarction, is half-dose reteplase plus abciximab more effective than reteplase alone? Study design. Secondary analysis of multicentre randomised controlled trial. Main results. For mortality at 30 days or 1 year, there was no significant difference between groups (see Table 1). Reteplase plus abciximab significantly reduced the risk of reinfarction, or recurrent ischaemia or angina compared with reteplase alone. A table is presented. Authors' conclusions. Although treatment with reteplase plus abciximab did not provide a survival benefit for people with diabetes and ST-segment elevation myocardial infarction compared with reteplase alone, nonfatal outcomes including reinfarction and recurrent ischaemia were substantially reduced.

Original languageEnglish (US)
Pages (from-to)230-231
Number of pages2
JournalEvidence-Based Healthcare
Volume8
Issue number4
DOIs
StatePublished - Aug 2004

Keywords

  • Acute myocardial infarction
  • Diabetes
  • Fibrinolytic therapy
  • Myocardial reperfusion
  • Randomised controlled trial

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Retaplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-segment elevation myocardial infarction'. Together they form a unique fingerprint.

  • Cite this